Associate Director, Publications

The role

The Associate Director, Publications will support the development and execution of publication plans for lifileucel and pipeline products. This person will work with cross-functional teams and healthcare professional experts to communicate accurate product information.

What you will do

• Support and facilitate comprehensive cross-functional global publication planning
• Execute publication plans and partner with agency partners
• Partner with Scientific Communications and Field Medical leads to support incorporation of published data into medical materials
• Ensure publication development and materials comply with Iovance policy and guidelines including ICMJE, PhRMA, and GPP
• Leverage best practices and implement efficient processes to optimize publication efforts
• Support the execution and implementation of iEnvision for publications management
• Act as subject matter expert and internal liaison for lifileucel and pipeline products
• Adhere to core values, policies, procedures, and business ethics

Required qualifications

• Advanced scientific/clinical degree (e.g., PharmD, Ph.D., MD) in a science-related field
• Experience in Cell Therapy or IO
• Experience in the development and medical writing of peer-reviewed publications and congress materials (abstracts, posters, presentations)
• Experience with Publication management systems such as Datavision
• Strong oncology writing experience
• Strong HEOR experience
• Experience with publications planning and execution, including literature gap analysis
• Excellent communication, organizational, and time management skills
• Experience in literature searches, literature evaluation, and drug information and educational concepts

Nice to have

• 10+ years relevant industry experience in medical/scientific publications either in the pharmaceutical industry or related (e.g., medical communication agency) industry

About the company

Iovance Biotherapeutics, Inc. is a global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. The company operates as an end-to-end cell therapy company with centralized U.S.-based manufacturing.